mRNA |
Doxorubicin |
GDSC1000 |
pan-cancer |
AAC |
-0.07 |
0.05 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.065 |
0.05 |
mRNA |
GSK-1904529A |
GDSC1000 |
pan-cancer |
AAC |
-0.066 |
0.05 |
mRNA |
YM-155 |
CTRPv2 |
pan-cancer |
AAC |
-0.072 |
0.05 |
mRNA |
ETP-46464 |
CTRPv2 |
pan-cancer |
AAC |
-0.082 |
0.05 |
mRNA |
tivozanib |
GDSC1000 |
pan-cancer |
AAC |
0.066 |
0.06 |
mRNA |
AT-7519 |
GDSC1000 |
pan-cancer |
AAC |
0.056 |
0.06 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.055 |
0.06 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.067 |
0.06 |
mRNA |
CIL70 |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.06 |